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Abstract
Background: Classically, vitamin D has been implicated in 
bone health by promoting calcium absorption in the gut and 
maintenance of serum calcium and phosphate concentra-
tions, as well as by its action on bone growth and reorganiza-
tion through the action of osteoblasts and osteoclasts cells. 
However, in the last 2 decades, novel actions of vitamin D 
have been discovered. The present report summarizes both 
classic and novel actions of vitamin D. Summary: 1,25(OH)2 
vitamin D, the active metabolite of vitamin D, also known as 
calcitriol, regulates not only calcium and phosphate homeo-
stasis but also cell proliferation and differentiation, and has 
a key a role to play in the responses of the immune and ner-
vous systems. Current effects of vitamin D include xenobi-
otic detoxification, oxidative stress reduction, neuroprotec-
tive functions, antimicrobial defense, immunoregulation, 
anti-inflammatory/anticancer actions, and cardiovascular 
benefits. The mechanism of action of calcitriol is mediated 
by the vitamin D receptor, a subfamily of nuclear receptors 
that act as transcription factors into the target cells after 
forming a heterodimer with the retinoid X receptor. This kind 
of receptors has been found in virtually all cell types, which 
may explain its multiple actions on different tissues. Key 
Messages: In addition to classic actions related to mineral 
homeostasis, vitamin D has novel actions in cell proliferation 
and differentiation, regulation of the innate and adaptative 
immune systems, preventive effects on cardiovascular and 
neurodegenerative diseases, and even antiaging effects.
© 2018 S. Karger AG, Basel
Introduction
Vitamin D was first characterized like a vitamin in the 
20th century and now it is recognized as a prohormone. 
Two major forms of vitamin D are vitamin D2 (ergocal-
ciferol) and vitamin D3 (cholecalciferol). Vitamin D3 is 
synthesized in the skin of humans and is consumed in the 
diet via the intake of animal-based foods, mainly fish oils, 
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whereas vitamin D2 is derived from plant sources, is not 
largely human-made, and added to foods [1]. Vitamins 
D2 and D3 forms differ only in their side chain structure 
(Fig.  1). The differences do not affect metabolism (i.e., 
activation), and both forms have the prohormone func-
tion.
Vitamin D Absorption and Photobiogenesis
Vitamin D obtained from sun exposure, food, and 
supplements is biologically inactive (either the vitamin 
D2 or D3) and must undergo activation through 2 con-
secutive enzymatic hydroxylation reactions occurring in 
the liver and kidney (Fig. 1).
Dietary vitamin D (either vitamin D2 or D3) is usually 
absorbed at the small intestine with other dietary fats [2]. 
The presence of fats in the lumen triggers bile acids re-
lease, which initiate emulsification and support the for-
mation of lipid-containing micelles, which diffuse into 
enterocytes [3]. Once absorbed, exogenous vitamin D is 
packaged into chylomicrons, and thus is transported to 
the liver. A fraction of the vitamin D contained in the chy-
lomicron can be taken up by adipose tissue and skeletal 
muscle [4]. Once remnant chylomicrons reach the liver, 
a specific carrier protein, the vitamin D binding protein 
(DBP) makes it possible for them to enter the hepatocytes 
and later facilitates their transport to different tissues that 
need them. Endogenously, vitamin D3 can be photosyn-
thesized in the skin.
7-Dehydrocholesterol (provitamin D3) is converted to 
the previtamin D3 form (precalciferol) following its expo-
sure to ultraviolet B (UVB) radiation [1]. Subsequently, it 
can suffer a thermal isomerization to vitamin D3 in the 
epidermis (Fig. 1). Alternatively, previtamin D3 may be 
photoconverted to nonactive forms, such as tachysterol 
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Fig. 1. Vitamin D forms, photobiosynthesis, and activation.
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and lumisterol, which may exert different biological ac-
tivities [5]. The production of vitamin D3 in the skin is 
due to the extent and quality of the UVB radiation reach-
ing the dermis as well as the availability of 7-dehydrocho-
lesterol and the characteristics of the skin.
Liver and Renal Metabolism of Vitamin D to the 
Active Hormonal Form
Once vitamin D enters the circulation through the skin 
or from the lymph, it is cleared by the liver or storage tis-
sues within a few hours. In the liver, precalciferol is rap-
idly hydroxylated by the 25-hydroxylase, a cytochrome 
P450 enzyme, (mainly the CYP2R1), which forms 25-hy-
droxyvitamin D (25(OH)2D; calcidiol), through an unreg-
ulated process [6]. Once synthesized, DBP-bound 25(OH)
D is secreted into blood and requires a renal hydroxylation 
to obtain the active form 1α,25 dihydroxyvitamin D (cal-
citriol). The average plasma life of 25(OH)D is around 
3 weeks; this is what makes serum levels of this 25(OH)D 
indicative of the body vitamin D storage and status.
When calcitriol is required due to a lack of calcium or 
phosphate, 25(OH)D is 1α-hydroxylated in the kidney 
forming the physiologically active form 1,25(OH)2D. 
This reaction is catalyzed by the 25(OH)D 1α-hydroxylase 
enzyme, which is another CYP450-dependent system 
(CYP27B1) [7]. This step occurs in the mitochondria of 
the proximal convoluted tubule cells, and is very tightly 
regulated by blood calcium and phosphate levels through 
parathyroid hormone (PTH) and the fibroblast growth 
factor 23 (FGF-23) [8]. Furthermore, 1,25(OH)2D can act 
as a suppressor of CYP27B1, although the mechanism is 
not fully understood. Vitamin D can be stored in the adi-
pose tissue, this accumulation being higher in obese than 
in normal weight subjects, but this stored vitamin D is not 
readily available, since it is not released when needed [9].
Inactivation and Excretion of Vitamin D
The CYP450 24-hydroxylase is present in the proximal 
convoluted tubule cells and in all target cells, expressing 
the vitamin D specific receptor (VDR). Calcitriol induces 
its own destruction by stimulating the 24-hydroxylase, 
which is also responsible for the degradation of its precur-
sor, 25(OH)D3. Several oxidation reactions follow this 
24-hydroxilation and sometimes the conjugation with 
glucuronic acid, thereby forming a number of com-
pounds excreted through the bile [6]. The renal excretion 
is usually very low (<5%). The DBP-vitamin D complex 
may be filtrated at the glomerulus and specifically re-up-
taken in a process mediated by a DBP-specific cubilin-
megalin receptor system [10].
Regulation of Vitamin D Metabolism
Regulation of calcitriol depends on the balance be-
tween 1α-hydroxylase and 24-hydroxylase activities. 
Both enzymes are rigorously regulated by serum calcium, 
calcitriol, and phosphate levels. Under low serum calcium 
conditions, or low levels of vitamin D, PTH secreted by 
the parathyroid glands stimulates the synthesis of the 
1α-hydroxylase, resulting in the increase of 1,25(OH)2D 
activation [11]. PTH also inhibits 24-hydroxylase [12], 
and can induce osteoclast and osteocytes synthesis of the 
FGF-23, which acts by reducing the expression of renal 
sodium-phosphate transporters [13]. FGF-23 can also ad-
just vitamin D homeostasis by suppressing renal expres-
sion of 1α-hydroxylase and inducing 24-hydroxylase, 
thus reducing serum calcitriol levels and subsequently se-
rum calcium under hyperphosphatemia conditions [14]. 
Classical Action of Vitamin D: Regulation of Calcium 
and Phosphate Homeostasis.
Calcitriol participates in the regulation of plasma ion-
ized calcium and phosphate levels by acting on their in-
testinal absorption, renal excretion, and calcium bone 
mobilization as described below (Fig.  2). When serum 
calcium levels decrease, PTH secretion is stimulated and 
activates calcitriol synthesis. Both PHT and calcitriol 
stimulate calcium renal reabsorption and mobilization 
from bones (bone resorption).
In contrast, if serum calcium levels rise, PTH secretion 
drops, leading to a decrease of calcitriol and calcium mo-
bilization. Indeed, if serum calcium levels become too 
high, the parafollicular cells of the thyroid secrete calcito-
nin, which block calcium mobilization from the bone and 
stimulate calcium and phosphorous excretion [15], con-
tribute to keep calcium levels within the normal range.
Calcitriol acts directly on 3 target tissues with the aim 
of maintaining optimal serum calcium levels. In addition, 
through VDR, calcitriol suppresses parathyroid gene ex-
pression and parathyroid cell proliferation, reinforcing 
its direct action on increasing serum calcium levels [16].
The first target organ is the intestine (without PTH 
mediation); here calcitriol stimulates intestinal calcium 
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absorption that depends on its presence in the diet, intes-
tinal solubility, and intestinal absorption capacity, which 
is the result of the balance between transcellular and para-
cellular intestinal absorption [2]. When calcium intake is 
high, paracellular transport will be sufficient [17]. Trans-
cellular transport involves 3 phases: (1) entrance of cal-
cium through specific calcium channels (such as TRPV6) 
present in membranes of the brush border; (2) intracel-
lular transport mediated by calbindin; and (3) calcium 
active transport to the blood stream at the basolateral sur-
face mainly mediated by specific carriers [2, 14, 17].
The second organ are the kidneys; calcitriol with PTH 
encourages the renal distal tubule reabsorption of calci-
um. Calcitriol influences (1) calcium entrance through 
the apical membrane; (2) calbamicin-mediated calcium 
diffusion; and (3) active transport thought the basolateral 
membrane [18]. Vitamin D inhibits phosphate reabsorp-
tion indirectly by increasing FGF-23 osteocytes expres-
sion, and directly by inducing α-klotho (FGF-23 co-re-
ceptor) [14].
The third target tissue is the bone. Calcitriol mobilizes 
calcium from bone, a process requiring PTH [19]. When 
serum calcium levels decrease, PTH-dependent calcitriol 
activation prompts the formation and VDR-mediated 
differentiation of osteoclasts. This activation induces the 
mobilization of calcium from the bone by stimulating the 
secretion of the receptor activator for nuclear factor kap-
pa-B ligand, which, in turn, is responsible for osteoclas-
togenesis and bone resorption [20]. At the same time, vi-
tamin D inhibits mineralization through the increase of 
pyrophosphate levels and osteopontin [21]. Calcitriol 
promotes bone formation and growth, by activating 
chondrocyte differentiation, and increasing serum calci-
um and phosphate levels. Thus, vitamin D deficiency re-
sults in inadequate mineralization of the skeleton, and 
when low vitamin D levels are maintained, bone growth 
plates cannot be mineralized due to calcium and phos-
phate depletion [22, 23].
Mechanisms of Action of Vitamin D
The mechanism of action of the calcitriol is mediated 
by the VDR, which belongs to a subfamily of nuclear re-
ceptors that act as transcription factors into the target 
cells after forming a heterodimer with retinoid X receptor 
(RXR). Once dimerized, the complex binds to the VDR 
element, in the promoter regions of target genes or at dis-
tant sites, to positively or negatively regulate their expres-
sion [24]. As the VDR has been found in virtually all cell 
types [25], it may explain its multiple actions on different 
tissues [26].
1,25(OH)2D3
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Besides 1,25(OH)2D3, the VDR-RXR dimer can asso-
ciate with other molecules as the p160 coactivators fam-
ily of steroid receptor coactivators 1, 2, and 3, that have 
histone acetylase (HAT) activity, and are primary coacti-
vators that bind to the AF2 domain of liganded VDR [27]. 
Members of p160 family recruit proteins as secondary co-
activators, such as CBP/p300, which also have HAT activ-
ity, resulting in a multi-subunit complex that modifies 
chromatin and destabilizes histone/DNA interaction 
[28]. The modification of histones occurs not only by 
acetylation, but also through methylation [27]. Liganded 
VDR interacts with basal transcription factors (TFIIB and 
several TATA DNA box binding protein-associated fac-
tors). VDR-intermediated transcription is facilitated by 
the mediator, a multi-protein complex that functions 
through the recruitment of RNA polymerase II and pro-
motes the formation of the preinitiation complex [29] 
(Fig. 3).
There is increasing evidence that specific CAAT en-
hance binding protein (C/EBP) family members may be 
key mediators of 1,25(OH)2D3 action. C/EBP is induced 
by 1,25(OH)2D3 in kidney and osteoblastic cells and co-
operates with 1,25(OH)2D3 and VDR in enhancing 
 Cyp24a1 and Bglap genes transcription [30]. C/EBP and 
VDR cooperate in the transcriptional regulation of the 
human antimicrobial peptide cathelicidin in lung epithe-
lial cells, and Runx2 and VDR collaborate in the tran-
scriptional regulation of mouse osteopontin in osteoblas-
tic cells [30]. C/EBP, Runx2, and VDR all contribute to 
the control of matrix metalloproteinase 13 gene tran-
scription [31]. The SWI/SNF complexes contribute to 
transcriptional activation by VDR. C/EBP recruits the 
SWI/SNF complex to promote 1,25(OH)2D3 induction of 
Cyp24a1 and Bglap transcription [32] (Fig. 3).
Low-affinity nutritional VDR ligands including cur-
cumin, polyunsaturated fatty acids, and anthocyanidins 
initiate VDR signaling, whereas the longevity factors res-
veratrol and sirtuin 1 potentiate VDR signaling [33]. The 
result of VDR genomic interactions is the transcription 
regulation of multiple genes, in many cases far from the 
cis site of VDR binding. However, in a few cases, VDR can 
exert a regulatory action in the absence of calcitriol.
The overarching principles of 1,25(OH)2D3-mediated 
gene regulation in target cells are as follows: i) VDR-
binding sites are about 2,000–8,000; ii) active transcrip-
tion unit is the VDR/RXR heterodimer; iii) distal-bind-
ing site location is dispersed in cis-regulatory modules 
(enhancers) across the genome; iv) VDR/RXR-binding 
site sequence (VDR element) is mediated by classic hex-


























Fig. 3. Molecular mechanism of action of vitamin D. CBP/p300; CREB-binding protein binding protein p300, 
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and repression is mediated by divergent sites; v) DNA 
mode of binding is predominantly, but not exclusively, 
1,25(OH)2D3-dependent; vi) enhancers contain binding 
sites for multiple transcription factors that facilitate both 
independent or synergistic interaction; vii) epigenetic 
enhancers signatures are defined by the dynamically reg-
ulated posttranslational histone H3 and H4 modifica-
tions and selectively regulated by 1,25(OH)2D3; viii) and 
VDR-binding sites are highly dynamic, as they change 
during cell differentiation, maturation, and disease acti-
vation and thus have consequential effects on gene ex-
pression [34]. Some mutations in the VDR affect severe-
ly its functionality causing rickets resistant to vitamin D, 
a rare autosomic recessive disease, also known as type II 
rickets. Those mutations modify the binding to VDR, the 
nuclear location of the calcitriol-receptor complex, the 
binding of the VDR to the cis elements, or the binding 
of VDR to some coactivators.
Novel Actions of Vitamin D
Vitamin D regulates cell proliferation and differentia-
tion and has a key role in the responses of the immune 
and nervous systems. In fact, observational studies sug-
gest that high serum concentrations of vitamin D protect 
against cardiovascular disease (CVD), diabetes, and 
colorectal cancer [35].
Evidence of extraskeletal effects of 1,25(OH)2D3 in-
cludes xenobiotic detoxification, oxidative stress reduc-
tion, neuroprotective functions, antimicrobial defense, 
immunoregulation, anti-inflammatory/anticancer ac-
tions, and cardiovascular benefits [27]. The first evi-
dence of novel activities of the vitamin D hormone was 
the demonstration that VDR was present in other tissues 
like keratinocytes, promyelocytes, monocytes, lympho-
cytes, ovarian cells, islet cells of the pancreas, and so on. 
[26].
Vitamin D and Cell Proliferation and Differentiation
Calcitriol and VDR have been shown to control the 
expression of genes associated with cellular proliferation 
and differentiation, suggesting a key role in cancer pre-
vention. There is some evidence that vitamin D levels 
provide a protective status to lower the risk of cancer. 
Some analyses on publications of colon, breast, prostate, 
and ovarian cancer revealed that in numerous cases, vi-
tamin D3 levels correlated with reduced incidence of 
cancer [36]. Conversely, other studies suggest no or only 
weak evidence for a link between vitamin D levels and 
cancer protection, and there are examples where high 
vitamin D levels may actually increase risk (pancreatic 
cancer) [37].
Preclinical studies show that calcitriol and its analogs 
have antitumor effects in vitro and in vivo through mul-
tiple mechanisms including the induction of cell cycle ar-
rest, apoptosis, differentiation, and the suppression of in-
flammation, angiogenesis, invasion, and metastasis [38].
The first demonstration that vitamin D was related to 
the terminal differentiation of promyelocytes to mono-
cytes was reported in 1981 [39]. Recently, calcitriol and 
several structurally related members of the vitamin D 
class of seco-steroids have demonstrated the ability to 
regulate the hedgehog (Hh) signaling pathway, respon-
sible of tissue differentiation during embryogenesis and 
maintenance of stem cell populations in certain adult tis-
sues.
In fact, dysregulation of Hh signaling results in its con-
stitutive activation and uncontrolled cellular prolifera-
tion and multiple mechanisms through which aberrantly 
activated Hh signaling contributes to tumor formation, 
growth, and metastasis [40]. Cross talk mechanisms be-
tween vitamin D/VDR signaling and the Hh pathway 
have not been well defined; however, evidence suggests 
that their interactions may play an important physiologi-
cal role, primarily in proper skin homeostasis and the on-
cogenic development of basal-cell cancer, which is the 
most common type of skin cancer. These mechanisms in-
clude the transcriptional control of Hh pathway compo-
nents by VDR as well as the ability of vitamin D ligands 
to directly modulate Hh pathway target genes [40]. To 
maintain tight control over calcitriol-mediated differen-
tiation, keratinocytes are capable of expressing all the en-
zymatic machinery necessary to produce and metabolize 
calcitriol. The levels of active CYP27A1 and CYP27B1 in 
keratinocytes are controlled by multiple factors including 
calcium levels, calcitriol concentration, UVB radiation, 
and stage of cellular differentiation, suggesting that the 
levels of calcitriol produced are tightly regulated at mul-
tiple stages [41].
Multiple studies have demonstrated the chemo-pre-
ventative and chemotherapeutic properties of both cal-
citriol and VDR in skin. Prolonged UVB radiation dam-
ages keratinocyte DNA, primarily through the formation 
of mutagenic cyclobutane pyrimidine dimers (CPDs). 
Direct topical administration of calcitriol or its analogues 
protected against CPD formation and increased CPD 
clearance [42].
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Vitamin D and the Immune System
1,25(OH)2D3 has important immunomodulatory ac-
tions, namely, the enhancement of the innate immune 
system and inhibition of the adaptative immune respons-
es, associated with an increased synthesis of interleukin 
(IL)-4 by T helper (Th)-2 lymphocytes and the upregula-
tion of regulatory T lymphocytes (T-reg). In fact, differ-
ent types of immune cells, for example, dendritic cells 
(DC), macrophages, and T and B lymphocytes express 
VDR and most of them are able to synthesize calcitriol 
through an independent regulation pathway responding 
to a number of proinflammatory agents as bacterial lipo-
polysaccharide and tumor necrosis factor alpha (TNF-α) 
[24].
Macrophages-derived cytokines promote Th differ-
entiation to Th0 cells. Later, with the cooperation 
of some costimulatory exogenous cytokines produced 
by a number of antigen presenting cells (APC), name-
ly, macrophages and DC, Th0 differentiate to Th1 or 
Th2 cells, which in turn regulates cell and antibody 
 immune responses. Calcitriol can regulate the im-
mune responses in secondary lymphoid organs as well 
as in target organs through a number of mechanisms 
(Fig. 4).
Regulation of the Innate Immune Response by DC and 
Macrophages
Calcitriol increases the defense capacity of macro-
phages inducing their differentiation, phagocytic capac-
ity, and antimicrobial activity (increasing the expression 
of cathelicidins). Moreover, calcitriol inhibits the prolif-
eration of monocytes, and promotes the differentiation of 
monocytes to macrophages, these effects being mediated 
by the upregulation of Fc surface cell receptors and by an 
increase in cell respiration. In addition, calcitriol inhibits 
DC proliferation, maturation, as well as their immuno-
stimulatory properties leading to the induction of T-reg 
cells. Consequently, vitamin D deficiency results in a less 
tolerogenic status to foreign antigens [26, 27].
Inhibition of the Pro-Inflammatory Response of APC
Calcitriol inhibits the expression of APC cytokines, 
namely, IL-1, IL-6, IL-12, and TNF-α and decreases the 
expression of a set of major histocompatibility complex 
class II cell surface proteins in macrophages, and the de-
velopment of proinflammatory Th1 and Th17 cells, while 
inducing T-reg and Th2 cells, which in turn downregulate 
the activity of Th1. Thus, calcitriol inhibits the produc-
tion of IL-12 and stimulates the production of IL-10, 

















































Fig. 4. Vitamin D effects on innate and adaptative immunity. CYP, cytochrome; MØ, macrophage; TH, T-helper 
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tory molecules, for example, clusters of differentiation 
(CD) CD40, CD80, and CD86, required for the activation 
of DC and other APC, leading to Th1 inhibition. Addi-
tionally, calcitriol acts directly on T cells inhibiting the 
secretion of IL-2, a cytokine essential for lymphocyte 
clonal expansion, and interferon gamma [26, 27].
Calcitriol also inhibits B cell differentiation and anti-
body production. Additionally, it inhibits the apoptosis 
of enterocytes and promotes the synthesis of antimicro-
bial peptides, and reduces the proliferation of keratino-
cytes in psoriasis, favoring cell differentiation in both cas-
es [26, 27].
Vitamin D and CVD
Experimental studies have established that calcitriol 
and VDR are critical regulators of the structure and func-
tion of the heart. In addition, clinical studies have associ-
ated vitamin D deficiency with CVD. Emerging evidence 
demonstrates that calcitriol is highly involved in CVD-
related signaling pathways, particularly the Wnt signaling 
pathway. Addition of calcitriol to cardiomyocyte cells 
demonstrated the (i) inhibition of cell proliferation with-
out promoting apoptosis; (ii) decreased expression of 
genes related to the regulation of the cell cycle; (iii) pro-
motion of the formation of cardiomyotubes; (iv) induced 
expression of casein kinase-1-α1, a negative regulator of 
the canonical Wnt signaling pathway; and (v) increased 
expression of noncanonical Wnt11, which has been rec-
ognized to induce cardiac differentiation during embry-
onic development and in adult cells [43].
Neuroprotective Effects of Vitamin D
Vitamin D metabolites naturally pass through the 
blood-brain barrier, giving them access to neuronal and 
glial cells. Therefore, a number of roles for vitamin D have 
been observed in various neurological/neuromuscular 
disorders [44]. It has also been proposed that microglia 
within the central nervous system can generate calcitriol 
in situ and this might represent an antitumor response. 
Calcitriol can inhibit the synthesis of inducible nitric ox-
ide synthase, leading to upregulation of glutathione; thus 
it could play a role in neuroprotection or neuromodula-
tion [34].
There is widespread expression of the VDR in the 
brain of adult rodents, with high levels found in sensory, 
motor, and limbic systems, suggesting a role for vitamin 
D throughout life. Expression of functional VDRs within 
both neurons and glia of the adult hippocampus provide 
further evidence for vitamin D’s importance in the adult 
central nervous system. In the human brain, both VDR 
and 1α-hydroxylase, the enzymes required for calcitriol 
production, have been observed to be in high levels in the 
substantia nigra, suggesting a potential link between this 
vitamin and the dopamine neuron population linked 
with Parkinson’s disease [26, 34].
Antiaging Activity of Vitamin D
Many of the health span advantages conferred by 
1,25(OH)2D3 are related to its induction of α-klotho, a 
renal hormone that is an antiaging enzyme/coreceptor 
that protects against skin atrophy, osteopenia, hyper-
phosphatemia, endothelial dysfunction, cognitive de-
fects, neurodegenerative disorders, and impaired hearing 
[33]. Together, 1,25(OH)2D3 and α-klotho maintain the 
molecular signaling systems that promote growth (p21), 
development (Wnt), antioxidation (Nrf2/FOXO), and 
homeostasis (FGF-23) in tissues crucial for normal phys-
iology, while simultaneously guarding against malignan-
cy and degeneration [45]. Hence, VDR liganded to 
1,25(OH)2D3 regulate the expression of set of genes re-
lated to health span, with the α-klotho target playing a key 
role in the facilitation of health span by delaying the 
chronic diseases of aging.
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